6-K

Securities and ExchangeCommission

Washington, D.C. 20549

Form 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d/16

of the Securities Exchange Act of 1934

April 2026

Aegon Ltd.

The Unaudited Pro Forma Consolidated Financial Information and notes thereto of Aegon Ltd. (the “Company”) herein are hereby incorporated by reference in the Company’s Registration Statements under the Securities Act of 1933, as amended, on Form F-3 (Registration No. 333-287291, 333-287291-01) and on Form S-8 (Registration Nos. 333-238186, 333-196156, 333-183176, 333-157843, and 333-150774).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Unaudited pro forma consolidated financial information of Aegon Ltd. relating to the

proposed sale of the Aegon UK plc

As ofDecember 31, 2025 and for the years ended December 31, 2025, 2024 and 2023

Introductory paragraph

The unaudited pro forma consolidated financial information presented below illustrates the financial impact on Aegon Ltd.’s (Aegon) consolidated statement of financial position as of December 31, 2025 and consolidated income statements for the years ended December 31, 2025, 2024 and 2023 of the proposed sale of Aegon UK plc (“Aegon UK”) containing the UK insurance and pensions operations to Standard Life Plc (“Standard Life”), a publicly traded company on the London stock exchange, that was announced on April 15, 2026. In connection with such sale, Aegon will receive GBP 750 million in gross cash proceeds and a 15.3% shareholding in Standard Life ordinary shares, with associated governance rights. Any remittances taken out of Aegon UK between the signing and closing of the transaction will be deducted from the GBP 750 million cash amount. Aegon’s asset management activities in the UK will remain part of Aegon’s global asset manager and will be an important asset management partner for the new combined business.

The transaction is expected to close around the end of 2026, subject to customary conditions, including regulatory approvals. The assets and liabilities of Aegon UK will be classified, for purposes of Aegon’s 1H 2026 consolidated financial statements, as held for sale. Related result will be presented as results from discontinued operations.

The unaudited pro forma consolidated financial information below complies with Article 11 of Regulation S-X and illustrates the impact of the proposed sale of Aegon UK on Aegon’s consolidated statement of financial position as of December 31, 2025 and Aegon’s consolidated income statements for the years ended December 31, 2025, 2024 and 2023. The unaudited pro forma consolidated statement of financial position has been prepared as if the sale had been consummated as of December 31, 2025. The unaudited pro forma consolidated income statements have been prepared as if the sale had been consummated as of January 1 of the respective years.

Historical financial information contains Aegon Ltd.’s audited consolidated financial information as presented in the Annual Report on Form 20-F 2025. The pro forma adjustments represent the financial impact of the proposed sale as described above. Pro forma adjustments are consistent with Aegon’s applicable financial reporting framework disclosed in the Annual Report 2025 on Form 20-F and with its accounting policies.

In each case, the pro forma data financial information is presented for illustrative purposes only and should not be relied upon as an indication of the financial condition or the operating results that would have been achieved if the Sale had taken place on the specified dates. In addition, future results may vary significantly from the results reflected in such pro forma financial information data and should not be relied on as an indication of future results.

Further information on the pro forma adjustments can be found in the notes to this unaudited pro forma financial information.

Unaudited pro forma Consolidated Income Statements of Aegon Ltd.

All values are in Euros.

Notes to the unaudited pro forma Consolidated income statement adjustments

Adjustments to Insurance service result reflect the elimination of the Insurance revenue and Insurance service expenses of Aegon UK. Insurance revenue mainly comprises expected insurance claims / expenses and CSM release; and Insurance service expenses mainly comprises the actual insurance claims / expenses.

Adjustments to Insurance net investment result reflect the elimination of the Insurance net investment result of Aegon UK. Insurance net investment result mainly comprises share dividends received by Aegon UK (Other investment income); fair value changes on Aegon UK’s investments (Results from financial transactions); and the Insurance finance expenses attributable to Aegon UK’s insurance contracts.

Adjustments to Other net investment result reflect the elimination of the other net investment result of Aegon UK. Other net investment result mainly comprises of fair value changes on Aegon UK’s investments related to investment contracts (Results from financial transactions); and the Investment contract expenses attributable to Aegon UK’s investment contracts portfolio.

Adjustments to Net result from continuing operations reflect the elimination of Aegon UK’s net result and includes inter-segment results between continuing Aegon Group entities and Aegon UK which are expected to discontinue.

Unaudited pro forma Consolidated statement of financial position of Aegon Ltd.

Notes to the unaudited pro forma Consolidated statement of financial position adjustments

Adjustments to Cash and cash equivalents of EUR 623 million represent the cash consideration to be received from Standard Life at the closing of the transaction (EUR 859 million) which is partially offset by the elimination of Aegon UK’s cash amount (EUR 200 million) and an estimate of the cost to be incurred by Aegon to sell the Aegon UK business (EUR 36 million).

Adjustments to Investments of EUR 123,599 million reflect the elimination of Aegon UK’s investments (EUR 125,128 million) partially offset by the share consideration to be received from Standard Life at the closing of the transaction.

All values are in British Pounds.

For the purpose of these unaudited pro forma numbers the 181 million shares to be received is multiplied by the GBP 7.37 closing stock price of Standard Life’s shares at the London stock exchange on December 31, 2025. FX conversion rate used is 0.8727, the EUR/GBP closing rate on December 31, 2025.

Adjustments to Shareholders’ equity of EUR 1,119 million reflect the receipt of the expected net consideration from the proposed transaction amounting to EUR 2,353 million offset by the derecognition of Aegon UK from Aegon’s consolidated statement of financial position for an amount of EUR 1,234 million.

Adjustments to ’Insurance contract liabilities and to Investment contract liabilities with / without discretionary participation features reflect the elimination of Aegon UK’s insurance contract liabilities and investment contract liabilities. These liabilities mainly consist of Platform, Packaged and Annuities related contracts.

Adjustments to Other assets and to Other liabilities reflect the elimination of Aegon UK’s other assets and other liabilities.